HO-3867, a STAT3 inhibitor induces apoptosis by inactivation of STAT3 activity in BRCA1-mutated ovarian cancer cells

References

• Daly MB, Axilbund JE, Buys S, Crawford B, Farrell CD, Friedman S, et al, National Comprehensive Cancer Network. Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw 2010; 8:562 - 94; PMID: 20495085
   PubMed Web of Science ®Google Scholar
• Fischer C, Engel C, Sutter C, Zachariae S, Schmutzler R, Meindl A, et al, on behalf of the German Consortium for Hereditary Breast and Ovarian Cancer. BRCA1/2 testing: uptake, phenocopies and strategies to improve detection rates in initially negative families. Clin Genet 2011; http://dx.doi.org/10.1111/j.1399-0004.2011.01788.x; PMID: 21919902
   PubMed Web of Science ®Google Scholar
• Lane TF. BRCA1 and transcription. Cancer Biol Ther 2004; 3:528 - 33; http://dx.doi.org/10.4161/cbt.3.6.843; PMID: 15254397
   PubMed Web of Science ®Google Scholar
• Schorge JO, Modesitt SC, Coleman RL, Cohn DE, Kauff ND, Duska LR, et al. SGO White Paper on ovarian cancer: etiology, screening and surveillance. Gynecol Oncol 2010; 119:7 - 17; http://dx.doi.org/10.1016/j.ygyno.2010.06.003; PMID: 20692025
   PubMed Web of Science ®Google Scholar
• Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003; 72:1117 - 30; http://dx.doi.org/10.1086/375033; PMID: 12677558
   PubMed Web of Science ®Google Scholar
• Chen S, Iversen ES, Friebel T, Finkelstein D, Weber BL, Eisen A, et al. Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol 2006; 24:863 - 71; http://dx.doi.org/10.1200/JCO.2005.03.6772; PMID: 16484695
   PubMed Web of Science ®Google Scholar
• Chetrit A, Hirsh-Yechezkel G, Ben-David Y, Lubin F, Friedman E, Sadetzki S. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. J Clin Oncol 2008; 26:20 - 5; http://dx.doi.org/10.1200/JCO.2007.11.6905; PMID: 18165636
   PubMed Web of Science ®Google Scholar
• Skytte AB, Waldstrøm M, Rasmussen AA, Crüger D, Woodward ER, Kølvraa S. Identification of BRCA1-deficient ovarian cancers. Acta Obstet Gynecol Scand 2011; 90:593 - 9; http://dx.doi.org/10.1111/j.1600-0412.2011.01121.x; PMID: 21371001
   PubMed Web of Science ®Google Scholar
• Boyd J, Sonoda Y, Federici MG, Bogomolniy F, Rhei E, Maresco DL, et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 2000; 283:2260 - 5; http://dx.doi.org/10.1001/jama.283.17.2260; PMID: 10807385
   PubMed Web of Science ®Google Scholar
• Rubin SC, Benjamin I, Behbakht K, Takahashi H, Morgan MA, LiVolsi VA, et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med 1996; 335:1413 - 6; http://dx.doi.org/10.1056/NEJM199611073351901; PMID: 8875917
   PubMed Web of Science ®Google Scholar
• Chirnomas D, Taniguchi T, de la Vega M, Vaidya AP, Vasserman M, Hartman AR, et al. Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. Mol Cancer Ther 2006; 5:952 - 61; http://dx.doi.org/10.1158/1535-7163.MCT-05-0493; PMID: 16648566
   PubMed Web of Science ®Google Scholar
• Banerjee S, Kaye S. PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond. Curr Oncol Rep 2011; 13:442 - 9; http://dx.doi.org/10.1007/s11912-011-0193-9; PMID: 21913063
   PubMedGoogle Scholar
• Scully R, Xie A, Nagaraju G. Molecular functions of BRCA1 in the DNA damage response. Cancer Biol Ther 2004; 3:521 - 7; http://dx.doi.org/10.4161/cbt.3.6.842; PMID: 15280660
   PubMed Web of Science ®Google Scholar
• Tassone P, Di Martino MT, Ventura M, Pietragalla A, Cucinotto I, Calimeri T, et al. Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo. Cancer Biol Ther 2009; 8:648 - 53; http://dx.doi.org/10.4161/cbt.8.7.7968; PMID: 19333003
   PubMed Web of Science ®Google Scholar
• Dayton A, Selvendiran K, Kuppusamy ML, Rivera BK, Meduru S, Kálai T, et al. Cellular uptake, retention and bioabsorption of HO-3867, a fluorinated curcumin analog with potential antitumor properties. Cancer Biol Ther 2010; 10:1027 - 32; http://dx.doi.org/10.4161/cbt.10.10.13250; PMID: 20798598
   PubMed Web of Science ®Google Scholar
• Selvendiran K, Ahmed S, Dayton A, Kuppusamy ML, Tazi M, Bratasz A, et al. Safe and targeted anticancer efficacy of a novel class of antioxidant-conjugated difluorodiarylidenyl piperidones: differential cytotoxicity in healthy and cancer cells. Free Radic Biol Med 2010; 48:1228 - 35; http://dx.doi.org/10.1016/j.freeradbiomed.2010.02.009; PMID: 20156552
   PubMed Web of Science ®Google Scholar
• Selvendiran K, Tong L, Vishwanath S, Bratasz A, Trigg NJ, Kutala VK, et al. EF24 induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by increasing PTEN expression. J Biol Chem 2007; 282:28609 - 18; http://dx.doi.org/10.1074/jbc.M703796200; PMID: 17684018
   PubMed Web of Science ®Google Scholar
• Selvendiran K, Ahmed S, Dayton A, Ravi Y, Kuppusamy ML, Bratasz A, et al. HO-3867, a synthetic compound, inhibits the migration and invasion of ovarian carcinoma cells through downregulation of fatty acid synthase and focal adhesion kinase. Mol Cancer Res 2010; 8:1188 - 97; http://dx.doi.org/10.1158/1541-7786.MCR-10-0201; PMID: 20713491
   PubMed Web of Science ®Google Scholar
• Selvendiran K, Tong L, Bratasz A, Kuppusamy ML, Ahmed S, Ravi Y, et al. Anticancer efficacy of a difluorodiarylidenyl piperidone (HO-3867) in human ovarian cancer cells and tumor xenografts. Mol Cancer Ther 2010; 9:1169 - 79; http://dx.doi.org/10.1158/1535-7163.MCT-09-1207; PMID: 20442315
   PubMed Web of Science ®Google Scholar
• Cook JA, Gius D, Wink DA, Krishna MC, Russo A, Mitchell JB. Oxidative stress, redox and the tumor microenvironment. Semin Radiat Oncol 2004; 14:259 - 66; http://dx.doi.org/10.1016/j.semradonc.2004.04.001; PMID: 15254869
   PubMed Web of Science ®Google Scholar
• Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?. Nat Rev Drug Discov 2009; 8:579 - 91; http://dx.doi.org/10.1038/nrd2803; PMID: 19478820
   PubMed Web of Science ®Google Scholar
• Blagosklonny MV. Prospective strategies to enforce selectively cell death in cancer cells. Oncogene 2004; 23:2967 - 75; http://dx.doi.org/10.1038/sj.onc.1207520; PMID: 15077157
   PubMed Web of Science ®Google Scholar
• Yu H, Jove R. The STATs of cancer--new molecular targets come of age. Nat Rev Cancer 2004; 4:97 - 105; http://dx.doi.org/10.1038/nrc1275; PMID: 14964307
   PubMed Web of Science ®Google Scholar
• Huang M, Page C, Reynolds RK, Lin J. Constitutive activation of stat 3 oncogene product in human ovarian carcinoma cells. Gynecol Oncol 2000; 79:67 - 73; http://dx.doi.org/10.1006/gyno.2000.5931; PMID: 11006034
   PubMed Web of Science ®Google Scholar
• Duan Z, Foster R, Bell DA, Mahoney J, Wolak K, Vaidya A, et al. Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer. Clin Cancer Res 2006; 12:5055 - 63; http://dx.doi.org/10.1158/1078-0432.CCR-06-0861; PMID: 16951221
   PubMed Web of Science ®Google Scholar
• Li L, Gao Y, Zhang LL, He DL. Concomitant activation of the JAK/STAT3 and ERK1/2 signaling is involved in leptin-mediated proliferation of renal cell carcinoma Caki-2 cells. Cancer Biol Ther 2008; 7:1787 - 92; http://dx.doi.org/10.4161/cbt.7.11.6837; PMID: 18787400
   PubMed Web of Science ®Google Scholar
• Gest C, Mirshahi P, Li H, Pritchard LL, Joimel U, Blot E, et al. Ovarian cancer: Stat3, RhoA and IGF-IR as therapeutic targets. Cancer Lett 2011; PMID: 22120672
   PubMed Web of Science ®Google Scholar
• Gao B, Shen X, Kunos G, Meng Q, Goldberg ID, Rosen EM, et al. Constitutive activation of JAK-STAT3 signaling by BRCA1 in human prostate cancer cells. FEBS Lett 2001; 488:179 - 84; http://dx.doi.org/10.1016/S0014-5793(00)02430-3; PMID: 11163768
   PubMed Web of Science ®Google Scholar
• Selvendiran K, Koga H, Ueno T, Yoshida T, Maeyama M, Torimura T, et al. Luteolin promotes degradation in signal transducer and activator of transcription 3 in human hepatoma cells: an implication for the antitumor potential of flavonoids. Cancer Res 2006; 66:4826 - 34; http://dx.doi.org/10.1158/0008-5472.CAN-05-4062; PMID: 16651438
   PubMed Web of Science ®Google Scholar
• Selvendiran K, Ahmed S, Dayton A, Kuppusamy ML, Rivera BK, Kálai T, et al. HO-3867, a curcumin analog, sensitizes cisplatin-resistant ovarian carcinoma, leading to therapeutic synergy through STAT3 inhibition. Cancer Biol Ther 2011; 12:837 - 45; http://dx.doi.org/10.4161/cbt.12.9.17713; PMID: 21885917
   PubMed Web of Science ®Google Scholar
• Huang Z. Bcl-2 family proteins as targets for anticancer drug design. Oncogene 2000; 19:6627 - 31; http://dx.doi.org/10.1038/sj.onc.1204087; PMID: 11426648
   PubMed Web of Science ®Google Scholar
• Kuwana T, Newmeyer DD. Bcl-2-family proteins and the role of mitochondria in apoptosis. Curr Opin Cell Biol 2003; 15:691 - 9; http://dx.doi.org/10.1016/j.ceb.2003.10.004; PMID: 14644193
   PubMed Web of Science ®Google Scholar
• Su SJ, Chow NH, Kung ML, Hung TC, Chang KL. Effects of soy isoflavones on apoptosis induction and G2-M arrest in human hepatoma cells involvement of caspase-3 activation, Bcl-2 and Bcl-XL downregulation and Cdc2 kinase activity. Nutr Cancer 2003; 45:113 - 23; http://dx.doi.org/10.1207/S15327914NC4501_13; PMID: 12791511
   PubMed Web of Science ®Google Scholar